FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365810895> ?p ?o ?g. }

• W4365810895 endingPage "2478" @default.
• W4365810895 startingPage "2469" @default.
• W4365810895 abstract "Ultrasound-guided radiofrequency ablation (RFA) has been used in patients with papillary thyroid carcinoma (PTC) who refuse surgery or active surveillance. However, the long-term outcomes are still limited. This study aimed to evaluate the clinical outcomes of RFA for solitary T1N0M0 PTC in a large cohort over a more than 5-year follow-up period.This retrospective study included 358 patients with solitary T1N0M0 PTC who were treated with RFA and followed for at least 5 years. The bipolar RFA procedure was performed using hydrodissection technique, transisthmic approach, and moving-shot technique. The primary outcomes were disease progression, including lymph node metastasis (LNM), recurrent tumor, persistent tumor, and distant metastasis. The secondary outcomes were volume reduction rate, complete disappearance rate, complications, and delayed surgery.During a mean follow-up period of 75.5 ± 9.7 months, the overall disease progression was 5.0%. The incidence of LNM, recurrent tumor, and persistent tumor was 1.4%, 3.1%, and 0.6%, respectively. There were no significant differences in the disease progression (5.0% vs. 5.5%, p = 1.000), LNM (1.3% vs. 1.8%, p = .568), recurrent tumor (3.3% vs. 1.8%, p = .872), persistent tumors (0.3% vs. 1.8%, p = .284), and 5-year recurrence-free survival rates (95.4% vs. 96.4%, p = .785) in the T1a and T1b groups. Volume reduction rate was 100.0 ± 0.3%, with 96.9% of tumors disappearing. No complications occurred. No patients underwent delayed surgery because of anxiety.RFA is an effective and safe alternative for patients with T1N0M0 PTC and can offer a minimally invasive curative option for patients who refuse surgery or active surveillance.During a mean follow-up period of 75.5 ± 9.7 months, the overall papillary thyroid carcinoma disease progression was 5.0%. The volume reduction rate was 100.0 ± 0.3%, with 96.9% of tumors disappearing. The T1a and T1b groups had similar incidence of disease progression and 5-year recurrence-free survival rates. No patients experienced complications or underwent delayed surgery because of anxiety." @default.
• W4365810895 created "2023-04-16" @default.
• W4365810895 creator A5023873686 @default.
• W4365810895 creator A5029556243 @default.
• W4365810895 creator A5045010032 @default.
• W4365810895 creator A5045433698 @default.
• W4365810895 creator A5079286679 @default.
• W4365810895 creator A5087218434 @default.
• W4365810895 date "2023-04-15" @default.
• W4365810895 modified "2023-10-14" @default.
• W4365810895 title "Clinical outcomes of ultrasound‐guided radiofrequency ablation for solitary T1N0M0 papillary thyroid carcinoma: A retrospective study with more than 5 years of follow‐up" @default.
• W4365810895 cites W2002739305 @default.
• W4365810895 cites W2018588853 @default.
• W4365810895 cites W2068973781 @default.
• W4365810895 cites W2114145339 @default.
• W4365810895 cites W2134604553 @default.
• W4365810895 cites W2145150141 @default.
• W4365810895 cites W2412145306 @default.
• W4365810895 cites W2518184411 @default.
• W4365810895 cites W2518315197 @default.
• W4365810895 cites W2605001594 @default.
• W4365810895 cites W2611699884 @default.
• W4365810895 cites W2620291523 @default.
• W4365810895 cites W2751120216 @default.
• W4365810895 cites W2807932048 @default.
• W4365810895 cites W2811417278 @default.
• W4365810895 cites W2891653457 @default.
• W4365810895 cites W2904830071 @default.
• W4365810895 cites W2909077836 @default.
• W4365810895 cites W2909918841 @default.
• W4365810895 cites W2911552134 @default.
• W4365810895 cites W2916972383 @default.
• W4365810895 cites W2965370400 @default.
• W4365810895 cites W2972765993 @default.
• W4365810895 cites W2990585145 @default.
• W4365810895 cites W3000116396 @default.
• W4365810895 cites W3044126849 @default.
• W4365810895 cites W3045572319 @default.
• W4365810895 cites W3090133621 @default.
• W4365810895 cites W3092387317 @default.
• W4365810895 cites W3097269601 @default.
• W4365810895 cites W3117837135 @default.
• W4365810895 cites W3128646645 @default.
• W4365810895 cites W3158830456 @default.
• W4365810895 cites W3165816081 @default.
• W4365810895 cites W3187335366 @default.
• W4365810895 cites W4211012370 @default.
• W4365810895 cites W4229440275 @default.
• W4365810895 cites W4285590251 @default.
• W4365810895 cites W4318934791 @default.
• W4365810895 doi "https://doi.org/10.1002/cncr.34802" @default.
• W4365810895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37060239" @default.
• W4365810895 hasPublicationYear "2023" @default.
• W4365810895 type Work @default.
• W4365810895 citedByCount "0" @default.
• W4365810895 crossrefType "journal-article" @default.
• W4365810895 hasAuthorship W4365810895A5023873686 @default.
• W4365810895 hasAuthorship W4365810895A5029556243 @default.
• W4365810895 hasAuthorship W4365810895A5045010032 @default.
• W4365810895 hasAuthorship W4365810895A5045433698 @default.
• W4365810895 hasAuthorship W4365810895A5079286679 @default.
• W4365810895 hasAuthorship W4365810895A5087218434 @default.
• W4365810895 hasConcept C120665830 @default.
• W4365810895 hasConcept C121332964 @default.
• W4365810895 hasConcept C121608353 @default.
• W4365810895 hasConcept C126322002 @default.
• W4365810895 hasConcept C126838900 @default.
• W4365810895 hasConcept C141071460 @default.
• W4365810895 hasConcept C167135981 @default.
• W4365810895 hasConcept C2777377203 @default.
• W4365810895 hasConcept C2778902805 @default.
• W4365810895 hasConcept C2779013556 @default.
• W4365810895 hasConcept C2993294228 @default.
• W4365810895 hasConcept C526584372 @default.
• W4365810895 hasConcept C61511704 @default.
• W4365810895 hasConcept C71924100 @default.
• W4365810895 hasConceptScore W4365810895C120665830 @default.
• W4365810895 hasConceptScore W4365810895C121332964 @default.
• W4365810895 hasConceptScore W4365810895C121608353 @default.
• W4365810895 hasConceptScore W4365810895C126322002 @default.
• W4365810895 hasConceptScore W4365810895C126838900 @default.
• W4365810895 hasConceptScore W4365810895C141071460 @default.
• W4365810895 hasConceptScore W4365810895C167135981 @default.
• W4365810895 hasConceptScore W4365810895C2777377203 @default.
• W4365810895 hasConceptScore W4365810895C2778902805 @default.
• W4365810895 hasConceptScore W4365810895C2779013556 @default.
• W4365810895 hasConceptScore W4365810895C2993294228 @default.
• W4365810895 hasConceptScore W4365810895C526584372 @default.
• W4365810895 hasConceptScore W4365810895C61511704 @default.
• W4365810895 hasConceptScore W4365810895C71924100 @default.
• W4365810895 hasIssue "16" @default.
• W4365810895 hasLocation W43658108951 @default.
• W4365810895 hasLocation W43658108952 @default.
• W4365810895 hasOpenAccess W4365810895 @default.
• W4365810895 hasPrimaryLocation W43658108951 @default.
• W4365810895 hasRelatedWork W1999439296 @default.
• W4365810895 hasRelatedWork W2013863777 @default.
• W4365810895 hasRelatedWork W2118389769 @default.

• next